Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib

Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes the...

Full description

Bibliographic Details
Main Authors: Jian Liu, Swan Lin, Anthony Huynh, Weiwei Tan
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Pharmaceutics
Subjects:
dacomitinib
EGFR inhibitor
overall survival
pharmacokinetics
progression-free survival
proton-pump inhibitors
Online Access:https://www.mdpi.com/1999-4923/16/1/118

Internet

https://www.mdpi.com/1999-4923/16/1/118

Similar Items